RemeGen Statistics

Total Valuation

RemeGen has a market cap or net worth of HKD 24.27 billion. The enterprise value is 26.42 billion.

Market Cap	24.27B
Enterprise Value	26.42B

Important Dates

The last earnings date was Monday, April 28, 2025.

Earnings Date	Apr 28, 2025
Ex-Dividend Date	n/a

Share Statistics

RemeGen has 536.84 million shares outstanding. The number of shares has increased by 0.51% in one year.

Current Share Class	181.81M
Shares Outstanding	536.84M
Shares Change (YoY)	+0.51%
Shares Change (QoQ)	+3.03%
Owned by Insiders (%)	11.63%
Owned by Institutions (%)	36.90%
Float	310.05M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	11.84
PB Ratio	12.78
P/TBV Ratio	13.91
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-17.94
EV / Sales	12.89
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-22.65

Financial Position

The company has a current ratio of 0.92, with a Debt / Equity ratio of 1.54.

Current Ratio	0.92
Quick Ratio	0.56
Debt / Equity	1.54
Debt / EBITDA	n/a
Debt / FCF	-2.51
Interest Coverage	-16.30

Financial Efficiency

Return on equity (ROE) is -56.64% and return on invested capital (ROIC) is -17.74%.

Return on Equity (ROE)	-56.64%
Return on Assets (ROA)	-15.27%
Return on Invested Capital (ROIC)	-17.74%
Return on Capital Employed (ROCE)	-44.47%
Revenue Per Employee	683,698
Profits Per Employee	-491,068
Employee Count	2,999
Asset Turnover	0.35
Inventory Turnover	0.52

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +18.31% in the last 52 weeks. The beta is 0.59, so RemeGen's price volatility has been lower than the market average.

Beta (5Y)	0.59
52-Week Price Change	+18.31%
50-Day Moving Average	26.68
200-Day Moving Average	17.86
Relative Strength Index (RSI)	57.10
Average Volume (20 Days)	11,410,976

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, RemeGen had revenue of HKD 2.05 billion and -1.47 billion in losses. Loss per share was -2.72.

Revenue	2.05B
Gross Profit	1.66B
Operating Income	-1.41B
Pretax Income	-1.47B
Net Income	-1.47B
EBITDA	-1.15B
EBIT	-1.41B
Loss Per Share	-2.72

Full Income Statement

Balance Sheet

The company has 773.80 million in cash and 2.93 billion in debt, giving a net cash position of -2.15 billion or -4.01 per share.

Cash & Cash Equivalents	773.80M
Total Debt	2.93B
Net Cash	-2.15B
Net Cash Per Share	-4.01
Equity (Book Value)	1.90B
Book Value Per Share	3.44
Working Capital	-197.46M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -939.57 million and capital expenditures -227.08 million, giving a free cash flow of -1.17 billion.

Operating Cash Flow	-939.57M
Capital Expenditures	-227.08M
Free Cash Flow	-1.17B
FCF Per Share	-2.17

Full Cash Flow Statement

Margins

Gross margin is 81.16%, with operating and profit margins of -68.89% and -71.83%.

Gross Margin	81.16%
Operating Margin	-68.89%
Pretax Margin	-71.83%
Profit Margin	-71.83%
EBITDA Margin	-56.09%
EBIT Margin	-68.89%
FCF Margin	n/a

Dividends & Yields

RemeGen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.51%
Shareholder Yield	-0.51%
Earnings Yield	-6.07%
FCF Yield	-4.81%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RemeGen has an Altman Z-Score of 0.96. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.96
Piotroski F-Score	n/a